Inhibrx Biosciences (INBX) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inhibrx Biosciences (INBX) has outperformed MeiraGTx (MGTX) over the past year, gaining 176.0% versus a gain of 27.1%. Inhibrx Biosciences is the larger company by market cap ($1.37 billion vs $1.01 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INBX | MGTX |
|---|---|---|
| Share price | $92.76 | $10.50 |
| Market cap | $1.37B | $1.01B |
| 1-day change | -0.64% | -2.96% |
| YTD return | +17.42% | +32.08% |
| 1-year return | +175.99% | +27.12% |
| 5-year return | — | -26.47% |
| P/E ratio (TTM) | — | 12.07 |
| EPS (TTM) | $-8.88 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $155.29 | $15.35 |
| 52-week low | $28.16 | $6.62 |
| Distance from 52-week high | -40.27% | -31.60% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +187.48% | +164.29% |
| Average volume | 284.58K | 792.38K |
| Shares outstanding | 14.72M | 96.04M |
| Employees | 109 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INBX has outperformed MGTX by 148.9 percentage points over the past year.
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
INBX vs MGTX FAQ
Which is bigger, Inhibrx Biosciences or MeiraGTx?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.37B compared with $1.01B for MeiraGTx (MGTX).
Which stock has performed better over the past year, INBX or MGTX?
INBX returned +175.99% over the past 12 months, compared with +27.12% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Are Inhibrx Biosciences and MeiraGTx in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.